Pharmacyclics (PCYC)
Pharmacyclics Revenue Growth: -6.41%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
PCYC Revenue Growth Rankings
| Overall | 19th percentile | 3529 of 4363 |
| Sector | 20th percentile | 363 of 457 in Healthcare |
| Industry | 35th percentile | 24 of 37 in Drug Manufacturers - Other |
PCYC Revenue Growth Range, Past 5 Years
| Minimum | -98.12% | Sep 2011 |
| Maximum | 2659% | Dec 2011 |
| Average | 399.3% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these PCYC related companies
PCYC News
$PCYC http://stks.co/43iw Consolidating very well.. keep an eye on it..
about 3 hours ago by vjtweet
about 3 hours ago by vjtweet
Worksheet for @stocktwits50 http://stks.co/40or $ARBA $LQDT $HAIN $EXPE $ALLT $ALGT $Z $ACHC $SXCI $PCYC
about 3 days ago by tradewithpete
about 3 days ago by tradewithpete
Headstart on whats working RT @StockTwits Best StockTwits50 Performers for the week: $ARBA $DDD $PCYC $EXPE $UA $Z http://stks.co/40RM
about 3 days ago by howardlindzon
about 3 days ago by howardlindzon
$vvus, $mdvn, $pcyc have done well, but they will explode once the market starts getting some traction again.
about 3 days ago by lennylex
about 3 days ago by lennylex
Best StockTwits50 Performers for the week: $ARBA $DDD $PCYC $EXPE $UA $Z http://stks.co/3zan
about 7 days ago by StockTwits
about 7 days ago by StockTwits
$PCYC http://stks.co/3y50 Looks to be getting a little overbought here. Lets see if it can keep running to end the week off.
about 8 days ago by ACInvestorBlog
about 8 days ago by ACInvestorBlog
$PCYC short-term target 35, intermediate-term 39. $VVUS if takes out wedge, look for test of highs around 26 1/4-1/2. http://stks.co/3wGp
about 10 days ago by thetechtrader
about 10 days ago by thetechtrader
El Gato Muerto | via @downtowntrader http://stks.co/3vn2 $SPY $FIRE $PCYC
about 10 days ago by STNet
about 10 days ago by STNet
$PCYC http://stks.co/3vlu This biotech is acting strong. A solid move into highs yesteday.
about 10 days ago by DanZanger
about 10 days ago by DanZanger
El Gato Muerto http://stks.co/3vlY via @DowntownTrader $PCYC $FIRE $SPY
about 10 days ago by StockTwits
about 10 days ago by StockTwits
$PCYC http://stks.co/3vaZ Broke out to new highs on solid volume. I think we will see some nice follow through tomorrow
about 10 days ago by ACInvestorBlog
about 10 days ago by ACInvestorBlog
$BWS http://stks.co/3vU7 $BWS $PVA $PCYC $FRO Full blog post here http://stks.co/3vU8
about 10 days ago by LincolnList
about 10 days ago by LincolnList
Notable 52-Week Highs and Lows of the Day 05/17: (ARRY) (NTES) (PCYC) High; (WFR) (VALE) (CLWR) Low
May 17, 3:42PM Street Insider
May 17, 3:42PM Street Insider
2012 Economic Outlook - Report Highlights Acorda Therapeutics Inc and Pharmacyclics, Inc.
May 17, 9:00AM Marketwire
May 17, 9:00AM Marketwire
Pharmacyclics, Inc. (PCYC) Posts Narrower than Expected Q1 Loss of 14c/Share
May 10, 6:40AM Street Insider
May 10, 6:40AM Street Insider
Pharmacyclics Reports Fiscal 2012 Third Quarter Financial Results and Recent Developments
May 10, 6:00AM PR Newswire
May 10, 6:00AM PR Newswire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| PCYC | 31.42 | -0.68 | -2.12% | 2.209B |
| PCY | 27.70 | +0.03 | +0.09% | |
| PCX | 2.37 | -0.01 | -0.42% | 221.15M |
| PCTI | 6.11 | +0.09 | +1.50% | 111.31M |
| PCS | 6.40 | +0.07 | +1.11% | 2.295B |
| PCRX | 10.62 | -0.05 | -0.47% | 271.12M |
| PCP | 166.21 | -0.41 | -0.25% | 24.19B |
| PCOM | 11.27 | +0.05 | +0.45% | 169.09M |
| PCN | 16.19 | +0.09 | +0.56% | |
| PCM | 10.94 | -0.03 | -0.27% |
